Advertisement

Novel Combinatorial Probiotics in Therapy and Prophylaxis

Chapter
  • 263 Downloads

Abstract

The microorganisms that are beneficial to health on consumption are known as probiotics, provided that they remain alive on consumption. The dosage and the administration regimen should be done considering the viability and survival of the microorganism in the acidic conditions prevailing in the stomach and intestinal region. Study of probiotics mainly involves the interaction of healthy microbiota and their associated interaction with host for health benefits. Studies implicated the effectiveness of live formulation of some lyophilized microorganisms such as Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei and Streptococcus thermophilus in small clinical trials. This chapter mainly highlights the use of probiotics in the inflammatory bowel disease (IBD). IBD includes two types of diseases: (i) Ulcerative colitis and (ii) Crohn’s disease. The common symptom of both the diseases involves severe diarrhoea, pain and weight loss. In ulcerative colitis, the patient develops ulcers in the innermost lining of the large intestine, colon and rectum and the resulting inflammation which sustains for longer duration of time. In Crohn’s disease, inflammation spreads out from the intestinal region and can affect entire gastrointestinal tract, i.e. from mouth to anus. As the rate of the prevalence of IBD is high in India and China, the novel approaches such as use of eco-compatible drugs are needed to combat the problems of antibiotic resistance.

References

  1. 1.
    Farrell RJ, Kelleher1 D (2003) Mechanisms of steroid action and resistance in inflammation: glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339–346Google Scholar
  2. 2.
    Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F (1992, June) Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 14(4):302–308Google Scholar
  3. 3.
    Al-Ataie MB, Shenovy VN (2005, October 4)Ulcerative colitis. e-MedicineGoogle Scholar
  4. 4.
    Mamula P, Markowitz J (2004, June/July) Ulcerative colitis and crohn disease. The eMedicine clinical knowledge base, Institutional EditionGoogle Scholar
  5. 5.
    Beattie RM (2005, July/Aug) Enteral nutrition as primary therapy in childhood Crohn’s disease: control of intestinal inflammation and anabolic response/discussion. J Parent Enter NutrGoogle Scholar
  6. 6.
    Fiocchi C (1997) Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 273:G769–G775PubMedGoogle Scholar
  7. 7.
    Plevy SE, Landers CJ, Carramanzana NM, Deem RL, Shealy D, Targan SR (1997) A role for TNF-alpha and mucosal T helper 1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 159:6276–6282PubMedGoogle Scholar
  8. 8.
    Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IL-5. J Immunol 157:1261–1270PubMedGoogle Scholar
  9. 9.
    Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F (1997) Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169–1178CrossRefPubMedGoogle Scholar
  10. 10.
    Hay JW, Hay AR (1992) Inflammatory bowel disease: costs of illness. J Clin Gastroenterol 14:309–317CrossRefPubMedGoogle Scholar
  11. 11.
    Bernstein CN et al (1999) Epidemiology of Crohn’s disease and ulcerative colitis in central Canadian province: a population-based study. Am J Epidemiol 149:916–924CrossRefPubMedGoogle Scholar
  12. 12.
    Hiatt RA, Kaufman L (1988) Epidemiology of inflammatory bowel disease in a defined northern California population. West J Med 149:541–546PubMedPubMedCentralGoogle Scholar
  13. 13.
    Yang SK et al (2000) Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986–1997. J Gastroenterol Hepatol 15:1037–1042CrossRefPubMedGoogle Scholar
  14. 14.
    Segal I et al (1980) The rarity of ulcerative colitis in South African blacks. Am J Gastroenterol 74(4):332–336PubMedGoogle Scholar
  15. 15.
    Loftus EV Jr et al (2000) Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut 46:336–343CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ouyang Q, Tandon R, Goh KL et al (2006) Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 21:1772–1782CrossRefPubMedGoogle Scholar
  17. 17.
    Selvam R et al (2009) Indian J Biochem Biophys 46:79–850PubMedGoogle Scholar
  18. 18.
    Chauvierre G (1992) J Gen Microbiol 138:1689–1696CrossRefGoogle Scholar
  19. 19.
    Wei S, Wu XB (2009 Sep) Key Lab of Dairy Science, Ministry of Education, College of Food Science and Engineering, Northeast Agricultural University 4;49(9):1247–1252 (20030066)Google Scholar
  20. 20.
    Bernet MF, Brassart D, Neeser JR, AL Servin Département de Microbiologie, UFR Sciences Pharmaceutiques, Paris, France (1994 Apr) Gut 35 (4):483–489 (8174985 Cit:178)Google Scholar
  21. 21.
    Coconnier MH, Lievin V, Hemery E, AL Servin Institut National de la Santé et de la Recherche Médicale, CJF 94. 07, UFR de Pharmacie, Université Paris XI, F-92296 Châtenay-Malabry, France (1998 Nov) Appl Environ Microbiol 64 (11):4573–4580 (9797324 Cit:81)Google Scholar
  22. 22.
    Chauvière G, Coconnier MH, Kernéis S, Fourniat J, AL Servin Département de Microbiologie et Immunologie, Université Paris XI, France (1992 Aug) J Gen Microbiol 138 Pt 8:1689–1696 (1527509 Cit:67)Google Scholar
  23. 23.
    Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, Moretti M, Vilarini I, Scassellati-Sforzolini R, I Rowland Institut für Ernahrungsphysiologie, Karlsruhe, Germany (1996) Nutr Cancer 26(3):365–380 (8910918 Cit:61)Google Scholar
  24. 24.
    Granato D, Perotti F, Masserey I, Rouvet M, Golliard M, Servin A, D Brassart Nestlé Research Center, CH-1000 Lausanne 26, Switzerland (1999 Mar) Appl Environ Microbiol 65(3):1071–1077 (10049865 Cit:57)Google Scholar
  25. 25.
    Bhatia SJ, Kochar N, Abraham P, Nair NG, A P Mehta Department of Gastroenterology, King Edward Memorial Hospital, Bombay, India (1989 Oct) J Clin Microbiol 27(10):2328–2330 (2511224 Cit:55)Google Scholar
  26. 26.
    Liévin-Le Moal V, Amsellem R, Servin AL, M-H Coconnier Institut National de la Santé et de la Recherche Médicale, Unité 510, Pathogénes et Fonctions des Cellules Epithéliales Polarisées, Faculté de Pharmacie, Université Paris XI, F-92296, Chãtenay-Malabry, France (2002 Jun) Gut 50 (6):803–811 (12010882 Cit:43)Google Scholar
  27. 27.
    McIntosh GH, Royle PJ, MJ Playne Division of Human Nutrition, Commonwealth Scientific and Industrial Research Organization, Adelaide, Australia (1999) Nutr Cancer 35 (2):153–159 (10693169 Cit:34)Google Scholar
  28. 28.
    Prashant K Jain, Clare E McNaught, Alexander DG Anderson, John MacFie, Charles J (2004) MitchellClin Nutr 23(4):467–475 (15297081 Cit:34s)Google Scholar
  29. 29.
    Vinderola CG, Reinheimer JA (1999) Culture media for the enumeration of Bifidobacterium bifidum and Lactobacillus acidophilus in the presence of yoghurt bacteria. Int Dairy J 9(497):505Google Scholar
  30. 30.
    Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795–803CrossRefPubMedGoogle Scholar
  31. 31.
    Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995) Antibodies to interleukin- 12 abrogate established experimental colitis in mice. J Exp Med 182:1281–1290CrossRefPubMedGoogle Scholar
  32. 32.
    Miller MJS, Sadowka-Kowicka H, Chotinnaueml S, Kakkis JL, Clark DA (1993) Amelioration of chronic ileitis by nitric oxide synthesis inhibition. J Pharmacol Exp Ther 264:11–16Google Scholar
  33. 33.
    Shibata Y, Taruishi M, Ashida T (1993) Experimental ileitis in dogs and colitis in rats with trinitrobenzenesulfonic acid-colonoscopic and histopathologic changes. Gastroenterol Jpn 28:518–552Google Scholar
  34. 34.
    Goldhill JM, Burakoff R, Donovan V, Rose K, Percy WH (1993) Defective modulation of colonic secretomotor neurons in a rabbit model of colitis. Am J Physiol 264:G671–G677PubMedGoogle Scholar
  35. 35.
    Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB (1996) Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 39:836–845Google Scholar
  36. 36.
    Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR (1996) Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 157:2174–2185PubMedGoogle Scholar
  37. 37.
    Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E (2016) The TNBS-induced colitis animal model: an overview. Ann Med Surg 11:9–15CrossRefGoogle Scholar
  38. 38.
    Ohkusa T (1985) Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and a change of intestinal microflora. Jpn J Gastroenterol 82:1327–1336Google Scholar
  39. 39.
    Okayasu I, Hatekeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and ulcerative colitis in mice. Gastroenterology 98:694–702CrossRefPubMedGoogle Scholar
  40. 40.
    Cooper HS, Murthy SNS, Shah RS, Seergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238–249PubMedGoogle Scholar
  41. 41.
    Murthy SN, Cooper HS, Shin H, Shah RS, Ibrahim SA, Sedergran DJ (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38:1722–1734CrossRefPubMedGoogle Scholar
  42. 42.
    Okayasu I, Ohkusa T, Kajiuar K, Kanno J, Sakamoo S (1996) Promotion of colorectal neoplasia in experimental colitis. Gut 39:87–92CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Iwanaga T, Hoshi O, Han H, Fujita T (1994) Morphological analysis of acute ulcerative colitis experimentally induced by dextran sulfate sodium in the guinea pig: possible mechanisms of cecal ulceration. J Gastroenterol 29:430–438Google Scholar
  44. 44.
    Domek MJ, Iwata F, Blackman EI, Kao J, Baker M, Vidrich A, Leung FW (1995) Antineutrophil serum attenuates dextran sulfate sodium-induced colonic damage in the rat. Scand J Gastroenterol 30:1089–1094Google Scholar
  45. 45.
    Sartor RB, Cromartie WJ, Powell DW, Schwab JH (1985) Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 89:587–595CrossRefPubMedGoogle Scholar
  46. 46.
    Ekstrom GM (1998) Oxazolone-induced colitis in rats: effects of budesonide, cyclosporine A, and 5-aminosalicylic acid. Scand J Gastroenterol 33:174–179CrossRefPubMedGoogle Scholar
  47. 47.
    Boirivant M, Fuss IJ, Chu A, Strober W (1998) Oxolozone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188:1929–1939CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Department of ZoologyUniversity of CalcuttaKolkataIndia

Personalised recommendations